CNS Pharmaceuticals Files 8-K Report

Ticker: CNSP · Form: 8-K · Filed: 2025-04-09T00:00:00.000Z

Sentiment: neutral

Topics: corporate-disclosure, 8-k

TL;DR

CNS Pharmaceuticals filed an 8-K on 4/9/25, updating its corporate information.

AI Summary

On April 9, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027. The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing serves as a public notification of the company's operational and reporting status with the SEC.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain new financial or operational information that would indicate increased risk.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing for CNS Pharmaceuticals, Inc.?

The 8-K filing is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a significant event or update for the company.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on April 9, 2025.

Where are the principal executive offices of CNS Pharmaceuticals, Inc. located?

The principal executive offices of CNS Pharmaceuticals, Inc. are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.

What is the state of incorporation for CNS Pharmaceuticals, Inc.?

CNS Pharmaceuticals, Inc. is incorporated in Nevada.

What is the company's telephone number as listed in the filing?

The company's telephone number, including area code, is (800) 946-9185.

From the Filing

0001683168-25-002373.txt : 20250409 0001683168-25-002373.hdr.sgml : 20250409 20250409153224 ACCESSION NUMBER: 0001683168-25-002373 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20250409 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNS Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001729427 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822318545 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39126 FILM NUMBER: 25825072 BUSINESS ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: 1-800-946-9185 MAIL ADDRESS: STREET 1: 2100 WEST LOOP SOUTH STREET 2: SUITE 900 CITY: HOUSTON STATE: TX ZIP: 77027 8-K 1 cns_8k.htm FORM 8-K 8-K false 0001729427 0001729427 2025-04-09 2025-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 9, 2025 ___________________________   CNS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ___________________________   Nevada 001-39126 82-2318545 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)   2100 West Loop South , Suite 900 Houston , Texas 77027 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (800) 946-9185   Not Applicable (Former Name or Former Address, if Changed Since Last Report) ___________________________   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbols(s) Name of each exchange on which registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Market LLC               Item 7.01. Regulation FD Disclosure.   On April 9, 2025, CNS Pharmaceuticals, Inc. (the “Company”) will use the presentation set forth as Exhibit 99.1 herein in connection with various meetings from time to time with the investment community..   The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and s

View on Read The Filing